# Study of SPG302 in Adults With Schizophrenia

> **NCT06442462** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Spinogenix** · enrollment: 32 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** SPG302
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06442462
- **Lead sponsor:** Spinogenix
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-08-01
- **Primary completion:** 2026-03
- **Final completion:** 2026-03
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06442462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06442462, "Study of SPG302 in Adults With Schizophrenia". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT06442462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*